158 related articles for article (PubMed ID: 21515509)
61. A meta-analysis of levetiracetam for randomized placebo-controlled trials in patients with refractory epilepsy.
Chen D; Bian H; Zhang L
Neuropsychiatr Dis Treat; 2019; 15():905-917. PubMed ID: 31043782
[TBL] [Abstract][Full Text] [Related]
62. [Pharmacology and clinical results of levetiracetam (E Keppra(®) Tablets), a new antiepileptic drug].
Ishii Y; Tanaka T
Nihon Yakurigaku Zasshi; 2011 Feb; 137(2):95-102. PubMed ID: 21321459
[No Abstract] [Full Text] [Related]
63. Levetiracetam in childhood epilepsy.
Verrotti A; D'Adamo E; Parisi P; Chiarelli F; Curatolo P
Paediatr Drugs; 2010 Jun; 12(3):177-86. PubMed ID: 20486734
[TBL] [Abstract][Full Text] [Related]
64. Efficacy and safety of prophylactic levetiracetam in supratentorial brain tumour surgery: a systematic review and meta-analysis.
Pourzitaki C; Tsaousi G; Apostolidou E; Karakoulas K; Kouvelas D; Amaniti E
Br J Clin Pharmacol; 2016 Jul; 82(1):315-25. PubMed ID: 26945547
[TBL] [Abstract][Full Text] [Related]
65. A meta-analysis of randomized controlled trials on levetiracetam in the treatment of pediatric patients with epilepsy.
Zhang L; Wang C; Li W
Neuropsychiatr Dis Treat; 2018; 14():769-779. PubMed ID: 29559784
[TBL] [Abstract][Full Text] [Related]
66. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam.
Kasteleijn-Nolst Trenité DG; Marescaux C; Stodieck S; Edelbroek PM; Oosting J
Epilepsy Res; 1996 Nov; 25(3):225-30. PubMed ID: 8956920
[TBL] [Abstract][Full Text] [Related]
67. Conclusions of the available meta-analyses exploring the efficacy of levetiracetam.
Tellez-Zenteno JF
Can J Neurol Sci; 2011 May; 38(3):388-9. PubMed ID: 21515492
[No Abstract] [Full Text] [Related]
68. Long-term safety, efficacy, and tolerability of levetiracetam in pediatric patients with epilepsy in Uygur, China: A retrospective analysis.
Zhao T; Li HJ; Yu J; Wang TT; Feng J; Ma L; Sun L; Sun Y; Yu LH
Epilepsy Behav; 2021 Jul; 120():108010. PubMed ID: 33964540
[TBL] [Abstract][Full Text] [Related]
69. The tolerability and efficacy of levetiracetam.
Tellez-Zenteno JF
Can J Neurol Sci; 2010 May; 37(3):309. PubMed ID: 20481263
[No Abstract] [Full Text] [Related]
70. Levetiracetam as adjunctive therapy for refractory anxiety disorders.
Kinrys G; Worthington JJ; Wygant L; Nery F; Reese H; Pollack MH
J Clin Psychiatry; 2007 Jul; 68(7):1010-3. PubMed ID: 17685735
[TBL] [Abstract][Full Text] [Related]
71. Comparative efficacy of prophylactic anticonvulsant drugs following traumatic brain injury: A systematic review and network meta-analysis of randomized controlled trials.
Wang BC; Chiu HY; Luh HT; Lin CJ; Hsieh SH; Chen TJ; Wu CR; Chen PY
PLoS One; 2022; 17(3):e0265932. PubMed ID: 35358219
[TBL] [Abstract][Full Text] [Related]
72. The adverse effects profile of levetiracetam in epilepsy: a more detailed look.
Mbizvo GK; Dixon P; Hutton JL; Marson AG
Int J Neurosci; 2014 Sep; 124(9):627-34. PubMed ID: 24256446
[TBL] [Abstract][Full Text] [Related]
73. Preventing seizure occurrence following spontaneous intracerebral haemorrhage: A systematic review and meta-analysis of seizure prophylaxis.
Tran QK; Bzhilyanskaya V; Afridi LZ; Ahmad M; Palmer J; Rehan MA; Raffman A; Rashid A; Menne A; Pourmand A
Seizure; 2021 Apr; 87():46-55. PubMed ID: 33713891
[TBL] [Abstract][Full Text] [Related]
74. Personalized prediction model for seizure-free epilepsy with levetiracetam therapy: a retrospective data analysis using support vector machine.
Zhang JH; Han X; Zhao HW; Zhao D; Wang N; Zhao T; He GN; Zhu XR; Zhang Y; Han JY; Huang DL
Br J Clin Pharmacol; 2018 Nov; 84(11):2615-2624. PubMed ID: 30043454
[TBL] [Abstract][Full Text] [Related]
75. Monotherapy trials in antiepileptic drugs: are modified "presurgical studies" a way out of the dilemma?
Bien CG; Elger CE
Epilepsy Res; 2001 Apr; 44(1):1-5. PubMed ID: 11255067
[TBL] [Abstract][Full Text] [Related]
76. Differences between men and women in response to antiseizure medication use and the likelihood of developing treatment resistant epilepsy.
Cepeda MS; Teneralli RE; Kern DM; Novak G
Epilepsia Open; 2022 Dec; 7(4):598-607. PubMed ID: 35939656
[TBL] [Abstract][Full Text] [Related]
77. Adjunctive clinical trials in epilepsy: is a placebo arm necessary?
Beydoun A; Kutluay E
Epilepsy Behav; 2003 Feb; 4(1):4-5. PubMed ID: 12609221
[No Abstract] [Full Text] [Related]
78. Can Pyridoxine Successfully Reduce Behavioral Side Effects from Levetiracetam?: A Critically Appraised Topic.
Chhabra N; Vanood A; Hoerth MT; Sanchez CV; O'Carroll CB
Neurologist; 2023 Sep; 28(5):349-352. PubMed ID: 37083708
[TBL] [Abstract][Full Text] [Related]
79. Effects of Levetiracetam on the Serum C-Reactive Protein in Children With Epilepsy: A Meta-Analysis.
Zhou YF; Huang Y; Liu GH
Front Pharmacol; 2022; 13():810617. PubMed ID: 35517802
[TBL] [Abstract][Full Text] [Related]
80. Levetiracetam Differentially Alters CD95 Expression of Neuronal Cells and the Mitochondrial Membrane Potential of Immune and Neuronal Cells in vitro.
Rogers SK; Shapiro LA; Tobin RP; Tow B; Zuzek A; Mukherjee S; Newell-Rogers MK
Front Neurol; 2014; 5():17. PubMed ID: 24600432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
